Intensity Therapeutics, Inc. (INTS) stock
INTSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.28+0.19 (+6.15%)
Close on Nov 11, 2026Market cap $10.71MP/E –Yield –
Intensity Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Intensity Therapeutics's operating income for the twelve months ending Sep 30, 2026 was -$12.37M. For fiscal 2025 it was -$11.97M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$11.97M | – |
| FY2024 | Dec 31, 2024 | -$16.59M | – |
| FY2023 | Dec 31, 2023 | -$8.32M | – |
| FY2022 | Dec 31, 2022 | -$7.55M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$3.62M | – |
| Q2 FY2026 | Jun 30, 2026 | -$3.08M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.53M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.14M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.73M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.71M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.39M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.20M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.57M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.07M | – |
| Q1 FY2024 | Mar 31, 2024 | -$4.74M | – |
| Q4 FY2023 | Dec 31, 2023 | -$3.35M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.49M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.22M | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.25M | – |
| Q4 FY2022 | Dec 31, 2022 | -$1.47M | – |
| Q3 FY2022 | Sep 30, 2022 | -$1.77M | – |
| Q2 FY2022 | Jun 30, 2022 | -$1.93M | – |
See a number that looks wrong?